Non-small cell lung cancer (NSCLC) therapy has experienced important changes in survival benefit and durable anti-tumor responses due to immune checkpoint blockers (ICBs). However, ICBs show some major limitations including low response rate drug resistance unselected patients. Despite the development of new predictive biomarkers, such as PD-L1 expression, microsatellite instability (MSI), or t...
